June 9th 2025
The Advisory Committee on Immunization Practices voted to lower the pneumococcal recommendation to 50 years in October 2024.
June 2nd 2025
The most common barriers to vaccination included finances, logistics, availability of information, and hesitancy or refusal.
Invasive pneumococcal disease is a cause of morbidity and mortality in the US, despite the availability of vaccination against the disease.
May 21st 2025
V116 is noninferior to 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all 12 common serotypes and superior to 9 unique serotypes.
May 20th 2025
Researchers estimate the cost-effectiveness of PCV24 in the older adult population compared with the currently accepted pneumococcal vaccine schedules in the US.
People with HIV Show Significantly Low Pneumococcal Vaccination Rates
Researchers wanted to better understand prescribing patterns of pneumococcal vaccines for people living with HIV in a tertiary care hospital.
Pneumococcal, Flu Vaccination Rates Low in Patients With Psychiatric Disorders
Patients with psychosis, depression, and anxiety exhibit higher rates of vaccine hesitancy.
Pneumococcal Carriage Decreases Following Vaccination for Children With HIV
Vaccination changes serotype distribution from vaccine-type serotypes to nonvaccine-type serotypes.
Pharmacist’s Knowledge, Attitudes, Beliefs Influence Patients Receiving Vaccination
Investigators specifically analyze information on influenza and pneumococcal vaccinations.
PCV13 Significantly Reduces Invasive Pneumococcal Disease in Pediatric Patients
Researchers explore trends from 2014 to 2022 among pediatric invasive pneumococcal diseases since introduction of the 13-valent pneumococcal conjugate vaccine.
PPSV23 Decreased Sinusitis, Antibiotic Use in Pediatric Patients
Researchers explored the association of a pneumococcal polysaccharide vaccine booster and health care utilization in children with sinusitis and low pneumococcal antibody titers.
Cost-Effectiveness of PCV15, 20 Vaccines Expected to Decrease
Using a cost-utility analysis, researchers addressed the cost-effectiveness of pneumococcal vaccine strategies for adults over the age of 64.
24-Valent Pneumococcal Conjugate Vaccine Shows Strong Immune Response in Infants
VAX-24 elicited substantial immunoglobulin G (IgG) and opsonophagocytic assay (OPA) immune responses at 1-month after the third dose across all doses studied.
Pneumococcal Disease Concerns Remain Despite Successful Vaccine Introduction
Researchers wanted to understand the distribution of pneumococcal conjugate vaccine serotypes and how they have potential to impact pneumococcal disease severity and burden.
Glucocorticoids May Reduce Mortality for Community-Acquired Pneumonia
Glucocorticoid use for severe community-acquired pneumonia has been controversial due to the safety profile of these drugs.
Mailing Campaign Feasible, Effective in Improving Pneumococcal Vaccine Rates
Researchers explored the efficacy of a targeted mailing campaign for improving pneumococcal vaccination coverage among adults 65 and over.
Knowledge Gaps Limit Pneumococcal Vaccination in Community Pharmacies
Investigators said that targeted education and interventions are key to the long term success of community pharmacy immunization programs.
State Immunization Policies for Pharmacists Hinder US Vaccine Uptake
IQVIA released a report detailing pharmacists’ authority to administer vaccines in the US as well as adults’ overall vaccination rates by state.
2025 ACIP Immunization Schedules
More detailed information can be found on the CDC’s website at www.cdc.gov/vaccines.
ACIP Publishes Final Pneumococcal Vaccine Recommendations
These recommendations were voted on at the October 2024 Advisory Committee on Immunization Practices meeting.
Simplifying Vaccine Access Translates to Better Uptake
Researchers explored ideas of simplifying the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.
Low Reimbursement, Coverage Restrictions Hinder Access to Vaccines
Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.
ACIP Votes to Lower Recommended Age of Pneumococcal Vaccination
The new recommendations suggest vaccination at age 50, rather than age 65.
Education Resources Affect Pharmacy Pneumococcal Vaccination Conversations
Pharmacist education can positively impact patient counseling around vaccinations in older adults.
Positive Topline Data From 31-Valent Pneumococcal Conjugate Vaccine Clinical Study Announced
The vaccine, VAX-31, targets 20 serotypes in common with PCV20, as well as 11 additional serotypes.
FDA Approves Pneumococcal 21-Valent Conjugate Vaccine Capvaxive
The vaccine covers 8 serotypes not currently covered by any FDA-approved pneumococcal vaccines.